Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

NCT03942653 is registered in ClinicalTrials.gov with Manish Patel as lead sponsor.

NCT NCT03942653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03942653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Lead sponsor
Manish Patel
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 30, 2019
Completion date
August 31, 2026
Enrollment
20 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

salivary gland carcinoma